Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INMB
stocks logo

INMB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.285
-28.75%
--
--
-0.310
-27.91%
--
--
-0.314
-70.1%
Estimates Revision
The market is revising No Change the revenue expectations for INmune Bio, Inc. (INMB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -3.59%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.91%
In Past 3 Month
Stock Price
Go Down
down Image
-3.59%
In Past 3 Month
Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.880
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 1.880
sliders
Low
8.00
Averages
8.00
High
8.00
Alliance Global Partners
Buy
downgrade
$20 -> $7
2025-07-03
Reason
Alliance Global Partners
Price Target
$20 -> $7
2025-07-03
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.
Maxim
Jason McCarthy
Buy
downgrade
$30 -> $8
2025-07-02
Reason
Maxim
Jason McCarthy
Price Target
$30 -> $8
2025-07-02
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on INmune Bio to $8 from $30 but keeps a Buy rating on the shares. The firm cites the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial, but while the top-line data is disappointing, there were some promising aspects and the company continues to develop its pipeline, the analyst tells investors in a research note.
Scotiabank
Outperform -> Underperform
downgrade
$23
2025-07-01
Reason
Scotiabank
Price Target
$23
2025-07-01
downgrade
Outperform -> Underperform
Reason
Scotiabank downgraded INmune Bio to Underperform from Outperform with a price target of 60c, down from $23, based on the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial. The firm think management's plan of securing CORDStrom FDA approval for treatment of recessive dystrophic epidermolysis bullosa has a "very low chance of success," the analyst tells investors.
BTIG
Buy -> Neutral
downgrade
$21
2025-06-30
Reason
BTIG
Price Target
$21
2025-06-30
downgrade
Buy -> Neutral
Reason
BTIG downgraded INmune Bio to Neutral from Buy and removed the firm's prior $21 price target after XPro Phase 2 data in early Alzheimer's disease, AD. The results marks another failure of anti-inflammatory approaches in the treatment of AD - despite the clear signs of inflammation in the brains of AD patients and the decades of animal work showing that CNS-inflammation is a negative regulator of neuronal and microglial function, the analyst tells investors in a research note.
Raymond James
Gary Nachman
Outperform -> Market Perform
downgrade
2025-06-30
Reason
Raymond James
Gary Nachman
Price Target
2025-06-30
downgrade
Outperform -> Market Perform
Reason
Raymond James analyst Gary Nachman downgraded INmune Bio to Market Perform from Outperform.
Raymond James
Outperform -> Market Perform
downgrade
$23
2025-06-30
Reason
Raymond James
Price Target
$23
2025-06-30
downgrade
Outperform -> Market Perform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for INmune Bio Inc (INMB.O) is -1.49, compared to its 5-year average forward P/E of -4.77. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.77
Current PE
-1.49
Overvalued PE
-2.46
Undervalued PE
-7.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2327.99
Current PS
0.00
Overvalued PS
7618.21
Undervalued PS
-2962.24
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INMB News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
INmune Bio Reveals New Neuroimaging Data Showing XPro1595 Slows Alzheimer's Progression
select
2025-10-30 (ET)
2025-10-30
16:41:03
INmune Bio announces Q3 earnings per share of 24 cents, below consensus estimate of 32 cents.
select
2025-09-29 (ET)
2025-09-29
08:19:51
INmune Bio presents Phase 2 MINDFuL trial findings to npj Dementia
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01Globenewswire
INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD
  • Clinical Trial Progress: INmune Bio presented new neuroimaging data for XPro1595 at the CTAD conference, indicating the drug may slow neurodegenerative progression in early Alzheimer's patients, highlighting its potential in treating inflammation-driven Alzheimer's disease.
  • Biomarker Validation: Utilizing PerpPD+ imaging analysis, the study observed a trend towards reduced cortical disarray in patients with high inflammatory burden receiving XPro1595, further validating its mechanism of selectively neutralizing soluble TNF (sTNF).
  • Market Opportunity: The findings underscore the unmet medical need for inflammation-driven Alzheimer's disease, positioning XPro1595 as a first-in-class disease-modifying therapy that could present significant commercial opportunities for the company.
  • Future Data Outlook: INmune Bio confirmed that additional MRI analyses will be released in 2026, expected to provide further insights into XPro1595's impact on brain tissue in Alzheimer's patients, enhancing its competitive position in the market.
[object Object]
Preview
9.0
09-15Newsfilter
INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult

  • Successful Manufacturing Milestone: INmune Bio Inc. has completed its first full-scale pilot commercial manufacturing run of CORDStrom™, a mesenchymal stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), at the Cell and Gene Therapy Catapult in the UK, paving the way for regulatory submissions in 2026.

  • Promising Clinical Results: CORDStrom™ has shown positive outcomes in a Phase 2 trial, improving symptoms such as itch, pain, and wound healing in RDEB patients, highlighting its potential as a life-changing therapy for those affected by this severe condition.

[object Object]
Preview
2.0
09-09NASDAQ.COM
INmune Bio (INMB) Declines 23.8% Over the Past Month, But a Trend Reversal Could Be Imminent

  • Stock Performance and Technical Analysis: INmune Bio, Inc. (INMB) has experienced a 23.8% decline over the past month, but its current RSI of 27.46 indicates it is oversold, suggesting a potential trend reversal may be imminent.

  • Analyst Sentiment and Earnings Estimates: There is strong consensus among analysts for improved earnings, with a 15.7% increase in the consensus EPS estimate over the last month, and INMB holds a Zacks Rank #2 (Buy), indicating a favorable outlook for the stock's recovery.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is INmune Bio Inc (INMB) stock price today?

The current price of INMB is 1.88 USD — it has increased 6.82 % in the last trading day.

arrow icon

What is INmune Bio Inc (INMB)'s business?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

arrow icon

What is the price predicton of INMB Stock?

Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is INmune Bio Inc (INMB)'s revenue for the last quarter?

INmune Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?

INmune Bio Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for INmune Bio Inc (INMB)'s fundamentals?

The market is revising No Change the revenue expectations for INmune Bio, Inc. (INMB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -3.59%.
arrow icon

How many employees does INmune Bio Inc (INMB). have?

INmune Bio Inc (INMB) has 22 emplpoyees as of December 05 2025.

arrow icon

What is INmune Bio Inc (INMB) market cap?

Today INMB has the market capitalization of 49.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free